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Abstract
Introduction: The aim of the research was to determine the effect of breakthrough pain (BTP) on heart and 
lung function in patients whose cancer pain had been treated with strong opiates. 
Methods: A prospective study was conducted on 80 patients who were treated in recumbent patients’ hos-
pice of Palliative Care Centre (hospice) University Clinical Centre Tuzla. The effect of pain breakthrough on 
heart function was monitored by blood pressure and pulse measuring outside. The effect on respiratory func-
tion was monitored by measuring the respiration number with SpO2 and pCO2 and pO2 capillary blood values 
outside, during and after relieving pain breakthrough. 
Results: Mean value for Karnofsky score for patients upon admission was 47.13 ± 11.05 and on discharge 
51.25 ± 11.73. The total number of pain breakthroughs for patients within the 10 days of the treatment was 
1396. During the pain breakthrough the mean of systolic pressure was 133.1 mmHg and it was statistically 
signifi cantly higher than the mean of systolic pressure measured after BTP relief with oral morphine. The 
mean of diastolic pressure measured outside of pain breakthrough was 75.9 mmHg and after the BTP relief 
it was 72.9 mmHg. The mean pulse outside of pain breakthrough was 92.7 heartbeats per minute and after 
the BTP relief 8 9.1 heartbeats per minute. 
Conclusion: Pain breakthrough leads to pulse acceleration, increased systolic and diastolic blood pressure 
and it also affects respiratory function by accelerating the respiration.  © 2011 All rights reserved
Keywords: breakthrough pain, heart and lung function
The effect of breakthrough pain on heart and 
lung function during the cancer pain treatment 
in palliative care
Samir Husić1*, Dženita Ljuca2, Senad Izić3, Hasan Karahasan4
1 Centre for Palliative Care, University Clinical Centre Tuzla, Trnovac bb, 75 000 Tuzla, Bosnia and Herzegovina. 2 Gynaecology 
and Obstetrics Clinic, University Clinical Centre, Trnovac bb, 75 000 Tuzla, Bosnia and Herzegovina. 3 Anaesthesia and 
resuscitation Clinic, University Clinical Centre, Trnovac bb, 75 000 Tuzla, Bosnia and Herzegovina. 4 Department of Gynaecology 
and Obstetrics, Cantonal Hospital Zenica, Crkvice 67, 72 000 Zenica. Bosnia and Herzegovina
Introduction
International Association for the Study of Pain – 
IASP, defi nes pain as an unpleasant sensory and 
emotional experience associated with actual or 
potential tissue damage, or described in terms of 
such damage. Pain is the most frequent and the 
most severe symptom of in cancer patients and 
75-90% of patients in terminal stage endure pain, 
the cause of cancer pain can be the cancer itself, 
cancer therapy or the accompanying disorders 
related to cancer pain. Tumour cells release en-
dothelin, prostaglandins, alpha tumour necrosis 
factor (TNF), proteolytic enzymes prostaglandins 
(E1 and E2), proinfl ammatory cytokines (TNF, IL-
1, IL-6), substance P, tumour growth factor and 
they also activate nociceptors that fi re spontane-
ously and create peripheral sensitization and fast 
tumour growth of diff erent types of tumours can 
lead to compression and nerve damage which 
causes ischemia and direct proteolysis (1). Tumour 
surgery can lead to nerve damage and neuropathic 
pain. Chemotherapy induces the release of algo-
genic cytokines, radiotherapy leads to tissue fi bro-
sis with nerve compression and painful mucositis 
can be caused both by radio and chemotherapy 
(2). Breakthrough pain (BTP) is a temporary sud-
den pain, a subtype of incidental pain that occurs 
over the “basic” pain during the opiate treatment. 
It should be diff erentiated from the weakly con-
trolled basic pain, which is also oft en a cause of 
the occurrence of pain breakthrough, also from 
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emergency pain and “crescendo pain”. When BTP 
occurs, basal pain is by defi nition relatively stable 
and under control (3). Th e governing committee of 
European Association for Palliative Care suggested 
the use of term “episodic pain” which they divid-
ed into two groups –with and without signifi cant 
basal pain (4). BTP by its intensity has to be severe 
to unbearable on basis of weak or medium severe 
pain. Portenoy and Hagen (5) described several 
characteristics that are important for understand-
ing the BTP: ratio of BTP with fi xed dose of opiates, 
temporal characteristics of BTP (duration period, 
time of occurrence), the cause of occurrence of 
BTP, possible predictability of the occurrence and 
pathophysiology and etiology of BTP (Table 1).
BTP occurs in 70-95% of the cases in patients in 
advanced stage of cancer disease (6). Th e intensity 
of BTP is oft en described as very severe and inten-
sive pain (from 7- 10 according to NRS (Numeri-
cal Rating Scale) with fast paroxysmal onset (<3 
minutes) and the mean of reaching the “pain peak” 
in less than 10 minutes. In 80-90% of the cases the 
duration is from 15 to 30 minutes and the mean 
frequency in patients in terminal stage of the can-
cer illness is 4-7 painful episodes a day (7). In 27% 
of the cases it occurs spontaneously, while the oc-
currence of the BTP can be accelerated by activi-
ties such as movements, laughter, sneezing, cough-
ing, sitting, touch, distension of hollow organs 
(bowels, urethra) or psychosocial stimuli (8). Th e 
cause of the BTP is most oft en related to bone pain 
(27%), local soft  tissue tumour invasion (21%) and 
brachial plexus syndrome (9%) , and it can be clas-
sifi ed as nociceptive, visceral nociceptive or neu-
ropathic (9). Two key components in treating BTP 
are: the size of individual salvage dose and tome 
interval of administering the drug. Most authors 
agree that the average “salvage dose” should be 10 
to 20% of total daily dose of fast-acting strong opi-
ate (10). In 17-30% of the cases, BTP is related to 
inadequate analgesic treatment, whether it is sub-
dosing analgesics or too long time interval between 
the doses, which leads to reduction of concentra-
tion in the plasma e.g. opiate in the end of dose 
interval which causes the increase of pain intensity 
so called end dose insuffi  ciency. At the same time 
the patients endure BTP not wanting to take fast-
acting opiate out of fear of side eff ects or develop-
ing resistance and addiction. Th e most frequently 
used drugs in BTP treatment are fast-acting oral 
opiates with the onset of 20 to 30 minutes aft er the 
administration, with maximal eff ect aft er 45 to 60 
minutes (11). Much better eff ects in relieving the 
BTP, because of its fast acting onset, are achieved 
with transmucosal fentanyl citrate, which passes 
through the blood brain barrier within 3-5 min-
utes, with its peak eff ect within 20-40 minutes 
with its overall duration from 2-3 hours aft er the 
administering the drug (12). Intranasally applied 
fentanyl citrate spray, relieves the episodic pain sig-
nifi cantly faster (within 5-10 minutes) in regard to 
oral morphine, with safe way of application, with-
out side-eff ects and good patient tolerance (13).
Th e aim of the research was to establish the ef-
fect of BTP on heart and lung function in patients 
whose cancer pain was treated with strong opiates.
Methods
Patients
A prospective study has been conducted on 80 
patients who were treated in recumbent patients’ 
hospice at Palliative Care Centre of Clinical Cen-
tre Tuzla in the period of September 2010 to 
March 2011. Basal Cancer pain (with 7-10 inten-
sity according to NRS) was treated with strong 
opiates (oral morphine and transdermal fentanyl) 
whose doses were increased every third day of 
the treatment by 50%, unless more than two pain 
breakthrough occurred the previous day, in which 
case a salvage dose of 8 mg of oral morphine was 
Basal cancer pain Breakthrough pain
Onset Sudden or occurring gradually Unexpected, sudden, unpredictable
Duration Persistent, lasts for at least 12 hours daily From few seconds to several hours, usually around 30 minutes
Characteristics Dull, painful, sharp Sharp, shooting, radiant
Treatment Long-lasting opiates with regular intake
Urgent therapy, immediately releasing or fast-acting 
opiates, intake according to the need
TABLE 1.  Differentiation of basal cancer and breakthrough pain
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required. General condition of the patients was as-
sessed using Karnofsky score upon admission and 
also aft er 10 days of treatment. Th e eff ect of pain 
breakthrough on heart function was monitored by 
measuring the blood pressure (systolic and dia-
stolic) and pulse outside, during and aft er reliev-
ing the BTP with salvage dose of oral morphine. 
Th e eff ect on respiratory function was monitored 
by measuring the number of respirations, values 
of SpO2 measured with pulse oksymeter pCO2 
and pO2-from ABS medical report, from capillary 
blood, outside, during and aft er relieving BTP by 
salvage dose of oral morphine. Th e study excluded 
the following patients; patients allergic to strong 
opiates, patients who have previously used strong 
opiates, patients with heavy vomiting that hin-
dered the intake of oral morphine, patients with 
increased value of pCO2 due to respiratory insuf-
fi ciency or as a sign of renal and liver insuffi  ciency.
Statistical analysis
Statistical analysis was conducted using biomedi-
cal application soft ware called MedCalc for Win-
dows version 9.4.2.0. For testing the repeated 
measurement of paired samples, depending on 
the distribution of variables, paired T-test and 
Wilcoxon tests were used. For testing the repeat-
ed measurements of samples with more than 2 
variables, ANOVA for repeated measurements 
was used. For testing the hypothesis of diff er-
ence in frequency of parameters of dichotomous 
scale, the test used was χ2 test. Statistical hypoth-
esis were tested based on the level of signifi cance 
of α = 0.05 meaning that the diff erence between 
samples was considered to be signifi cant if p < 0.05.
Results 
Mean value for Karnofsky score for all 80 pa-
tients upon admission was 47.13 ± 11.05 
and on discharge 51.25 ± 11.73, and aft er re-
lieving the pain Karnofsky score was sta-
tistically signifi cantly better (p = 0.0005).
Th e total number of pain breakthroughs in all 
80 patients within 10 days of treatment was 
1396 (1.75 breakthroughs per patient a day). On 
the fi rst day of treatment, total number of pain 
breakthroughs was 208 (2.6 breakthroughs per 
patient a day), on the second day it was 184, and 
on the third day 186 BTP (2.3 breakthrough/per 
patient/a day). On the fourth day of the treat-
ment the total of 160 BTP were noted (2.0 break-
throughs/per patient/a day) which is statistically 
signifi cantly less compared to the fi rst day (p= 
0.008). Also, in the following days, the BTP kept 
reducing and on the tenth day total of 53 BTP was 
registered (0.66 breakthroughs/per patient/a day), 
which is statistically signifi cantly less compared to 
the day of the admission (p< 0.0001) (Figure 1).
Th e eff ect of BTP on cardiovascular system
During the BTP, mean value of systolic pressure 
in all 80 examinees (in 1396 measurements) was 
133.1 mm Hg (from 115 do 165 mm Hg) and was 
statistically signifi cantly greater (p< 0.0001) than 
systolic pressure mean measured in a state of 
stabile, controlled pain (outside BTP) when the 
mean was 120.4 mm Hg (from 100 to 140 mm 
Hg). Aft er relieving BTP by salvage dose of oral 
morphine the mean of systolic pressure was 114.5 
mm Hg (from 80 to 140 mm Hg) and was statis-
tically signifi cantly lower (p<0.0001) compared to 
the systolic pressure during the BTP (Figure 2).
Th e mean of diastolic pressure in all 80 examinees, 
monitored outside BTP was 75.9 mm Hg (from 60 
to 95 mm Hg). During the BTP the mean of dia-
stolic pressure (in 1396 measurements) was 84.7 
mm Hg (from 70 to 130 mm Hg) and was statis-
tically signifi cantly higher (p<0.0001) compared 
to measuring outside BTP. Th e value of diastolic 
pressure aft er relieving the BTP with salvage dose 
of oral morphine was 72.3 mm Hg (from 50 to 95 
mm Hg) and was statistically signifi cantly lower 
(p< 0.0001) compared to diastolic pressure during 
the BTP (Figure 2). Measured outside BTP, mean 
pulse in for all 80 patients was 92.7 heartbeats per 
minute (From 78 to 110 heartbeats per minute). 
During the BTP statistically signifi cant pulse ac-
celeration occurs (p< 0.0001) so the mean rises to 
102.2 heartbeats per minute (from 83 to 120 heart-
beats/min), followed by signifi cant pulse slow 
down aft er relieving the BTP with oral morphine 
(p< 0.0001), so the mean shows 89.1 heartbeats per 
minute (from 64 to 107 heartbeats/min) (Figure 2).
Th e eff ect of breakthrough pain on respiratory system
Th e mean number of respirations, measured in 
a state of stabile, controlled pain was 13.6 per 
minute (from 12 to 16), with statistically sig-
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nifi cant respiration acceleration (p<0.0001) 
during the BTP to the mean of 15.6 per minute 
(from 12 to 21 respirations per minute). Reliev-
ing BTP with salvage dose of oral morphine 
signifi cantly slows down the respiration speed 
(p<0.0001) so the mean number of respirations 
per minute is 12.8 (from 11 to 16) (Figure 3).
Th e mean of partial pressure of carbon dioxide 
in capillary blood (pCO2) in all 80 patients out-
side BTP was 40.2 mm Hg (from 29.6 to 51.1 
mm Hg) while during the BTP statistically sig-
nifi cant (p< 0.0001) increase of pCO2 to the mean 
of 44.2 mm Hg occurred (from 30.2 to 57.2 mm 
Hg), and relieving BTP with salvage dose of oral 
morphine signifi cantly reduces the mean of pCO2 
mm Hg (from 28.3 to 51.1 mm Hg) (Figure 4).
Partial pressure of oxygen (pO2) in capillary blood 
in all patients outside BTP in mean was 75.9 mm 
Hg (from 62.7 to 91.6 mm Hg) and is statistically 
signifi cantly higher (p< 0.0001) than pO2 mean 
during BTP, which was 71.9 mm Hg (from 55.7 to 
88.4 mm Hg) on mean. By relieving the pain by 
salvage dose of oral morphine the ventilation im-
proves so the mean of pO2 was 77.7 mm Hg (63.1 
to 92.7 mm Hg), which is statistically signifi cantly 
higher (p< 0.0001) than during BTP (Figure 4).
Th e saturation mean (SpO2%) measured with 
pulse oximeter in all 80 patients, monitored out-
side BTP was 92.8 % (from 83 to 96%) only to 
be statistically signifi cantly smaller during the 
BTP (p<0.0001) when it was 89.1 % (from 79 to 
96%) and aft er relieving BTP with oral morphine, 
the mean SpO2 94.5% (from 84 to 98%) and it 
was statistically signifi cantly higher (p<0.0001) 
compared to the means of SpO2 during BTP 
but also before the onset of BTP (Figure 4). 
Discussion 
In the study that monitored the eff ects of cancer 
pain treatment with transdermal fentanyl within 
FIGURE 1.  Number of BTP through days of treatment in all 
examinees
FIGURE 2.  The values of blood pressure and pulse depend-
ing on BTP
FIGURE 3.  The mean of respirations per minute depending 
on the number of BTP
FIGURE 4.  The mean of pCO2, pO2 and SpO2 depending on 
BTP
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the period of 3 months, Karnofsky score was 
relatively constant during the treatment, with the 
mean of 69 ± 2 on the fi rst day, 68 ± 2 at the end 
of the second month and 69 ± 2 at the end of the 
study (14). In our study, mean value of Karnofsky 
score for all 80 patients upon admission was 47 ± 
11.05 and upon release 51.25 ± 11.73, so aft er re-
lieving the pain Karnofsky score was signifi cantly 
better (p=0.0005). Th e study of Marinangeli and 
associates on 48 patients in advanced stage of 
carcinoma showed, contrary from our study, that 
aft er the opiate treatment with the average dura-
tion of 76.66 ± 41.15 and signifi cant reduction of 
pain intensity (p = 0.04), statistically signifi cant 
reduction of Karnofsky performance status oc-
curs (from 58.92 ± 5.56 upon admission, with the 
reduction of – 24.04) and the degree of life qual-
ity, shows deterioration of general condition (15). 
In our study, aft er relieving the pain with strong 
opiates, dyspnea was statistically signifi cantly re-
duced (p< 0.0001; 4.41 ± 2.13 compared to 1.95 
± 1.43. BTP signifi cantly accelerates respiration, 
but no considerable diff erence was noted com-
pared to the number of respirations before the 
BTP (13.6/min) and aft er relieving the pain with 
strong opiates (12. 8/min). A study published for 
palliative care units in Japan states that dyspnea 
occurs in 29 to 74% of the patients, regardless of 
the type of carcinoma in terminal stage of the ill-
ness, in which respiratory depression treated by 
morphine is defi ned as deceleration of breathing 
by more than 10% and it reduces SpO2 by more 
than 5. Th e mean dose of morphine used was 65 
mg/per day/per patient (in our study 52.42 mg 
within all ten days of the treatment.) Also, in our 
study, there was no signifi cant diff erence in the 
number of respirations (p= 0.117) before and af-
ter the application of morphine. In this study the 
mean of oxygen saturation (SpO2%) measured by 
pulse oximeter was around 88% before, and up to 
98% aft er the morphine treatment (p=0.125), and 
as well as in our study there was no statistically 
signifi cant diff erence. Th is study concurrently 
draws a conclusion that if the morphine is applied 
in the form of nebulizer (if it is inhaled) it relives 
the breakthrough pain or sudden onset of dys-
pnea signifi cantly faster and it has far less system 
side eff ects (constipation, drowsiness etc.) (16).
In random double-blind controlled study con-
ducted in Switzerland in older patients in which 
dyspnea was treated with 5 mg s.c. of morphine, 
measuring taken 45 minutes aft er the treatment 
show, like in our study, a signifi cant (p<0.01 re-
duction of pain intensity [(according to VAS scale: 
57.8 ± 16 before compared to 32.8 ± 15 aft er the 
morphine treatment, while in the placebo group 
control measuring shows aggravation of pain from 
50.6 ± 18 before, compared to 51.1±15 aft er the 
application of the placebo)]. Th e number of respi-
rations aft er the morphine treatment was smaller 
(-2 ± 2.2), while in the placebo group there was no 
diff erence in the number of respirations (p=0.02) 
compared to experimental and placebo group. In 
this particular study, as well as in our study, there 
was no signifi cant diff erence in blood oxygen satu-
ration before and 45 minutes aft er the morphine 
treatment (0 ± 1.5). Th e study concludes that the 
morphine reduces dyspnea in patients suff ering 
from cancer without any signifi cant side-eff ects, 
with the use of one quarter of regular 4-hour 
dose of morphine used in pain treatment (17). 
A study by Estefan and associates follows simi-
lar parameters in 30 patients in terminal stage 
of cancer disease that is not dependent on oxy-
gen therapy. Th ere was no statistically signifi -
cant change (p = 0.14) in values of end-tidal CO2 
(values before 33.39 ± 5.0 compared to means 
aft er 34.79 ± 5.7 mm Hg) aft er the morphine 
treatment which lead to signifi cant reduction of 
pain intensity. In our study as well, there is no 
signifi cant change in the mean of partial pres-
sure in the capillary blood (pCO2) before and aft er 
the treatment with oral morphine [39.9 mm Hg 
(from 29.6 to 51.1 mm Hg) before compared to 
38.2 mm Hg (from 28.3 to 50.8 mm Hg) aft er the 
treatment], although, contrary to the Estefan and 
associates study, the means of pCO2 in our study 
were somewhat higher aft er the treatment (18). 
A Study conducted at St. Christopher Hospice 
monitors the eff ect of oral morphine on respira-
tory function in 31 patients. All patients received 
over 100 mg morphine sulphate a day in the av-
erage doses of 30 mg for every 4 hours (from 20 
to 90 mg). Th e diagnoses of cancer were set ap-
proximately 11 moths (from 3 to 174 months) 
before the admission to hospice. Following the 
value of respiratory parameters blood PH was in 
the range from 7.33 to 7.48, pCO2 from 25.8 to 
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52.1 mm Hg, pO2 from 48.3 to 123.5 mm Hg and 
HCO3 from 13.3 to 28.3 mmol/l. Th e study con-
cludes that the appropriate dose of titration of 
oral morphine (regardless of its plasma level) re-
lieves pain well and in addition to that it provides 
safety from developing respiratory depression in 
cancer pain. In our study, relieving the pain leads 
to reduction of pCO2 (from 44.6 mm Hg to 38.2 
mm Hg), the increase of mean of pO2 (from 71.4 
mm Hg to 78.1 mm Hg), and also the increase of 
SpO2 from 89.1% during the breakthrough pain to 
94.5% aft er relieving the breakthrough pain (19). 
 While the eff ect of acute pain on heart function 
has been studied thoroughly, there are few studies 
that talk about the eff ect of chronic pain on blood 
pressure and heart frequency. Th e research by Ra-
dosh et al. (2009) follows the impact of chronic 
pain treatment effi  ciency on heart function. Th e 
research was conducted on 37 patients whose 
pain was determined by numerical scale (from 0 
to 10), and the treatment, depending on pain in-
tensity was conducted accordingly to the guide-
lines of tree level scale. Th e pain intensity during 
the fi rst check-up was on average 8 (from 6, 0 to 
10, 0), during the fi rst control check-up 5 (from 
2.7 to 6.5) and 4 (from 2.5 to 5.3) during the third 
examination which is statistically signifi cantly less 
(p<0.001). Th e mean of systolic pressure was, as in 
our study as well, signifi cantly reduced (p<0.001) 
aft er relieving the pain, at the control check–up 
compared to the fi rst examination [130 (from 
120 to 148 mm Hg) compared to 150 (from 130 
to 160 mm Hg) ]. Th e mean of diastolic pressure 
was signifi cantly reduced (p<0.007) at the control 
check-up [90 (out of 80 to 98 mm Hg) compared 
to 80 (from 80 to 88 mm Hg)] which corresponds 
with the results of our study, while contrary to 
the results of our study, in this research there 
was no signifi cant diff erence in the heart func-
tion frequency [p = 0.821; 78 (72 to 83 per min-
ute) compared to 78 (71 to 83 per minute)] (20).
Conclusion 
Breakthrough pain, as an “acutization” of chronic 
cancer pain aff ects the cardiovascular system lead-
ing to pulse acceleration, increase of systolic and 
diastolic blood pressure. Breakthrough pain af-
fects the respiratory function by leading to respi-
ration acceleration, the increase of pCO2 values, 
and the reduction of pO2 and SpO2 values, with-
out statistically signifi cant diff erence in relation to 
mentioned parameters before the onset of break-
through pain. By using modern fast-acting opiates 
such as transmucosal fentanyl citrate or interna-
sal fentanyl citrate spray, the breakthrough pain 
is much more easily intercepted (within 5- 10) 
minutes and by doing that the eff ect of BTP on 
cardiovascular and respiratory system is reduced. 
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